New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 3, 2013
07:41 EDTBIIBBiogen drops 7% after ALS drug misses endpoint in trial
Shares of Biogen Idec (BIIB) are down 7% in pre-market trading after the company said its Phase 3 trial investigating dexpramipexole in people with amyotrophic lateral sclerosis, or ALS, did not meet its primary endpoint. Biogen said it will discontinue development of dexpramipexole in ALS due to the trial results. Note earlier this morning, Piper Jaffray cut its rating on shares of Biogen to Neutral from Overweight. The stock is currently trading lower 7%, or $10.01, to $139.99 in pre-market trading.
News For BIIB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 25, 2014
11:08 EDTBIIBBiogen to add PML info on Tecfidera label after patient dies
Subscribe for More Information
11:04 EDTBIIBFDA says Biogen adding PML information on Tecfidera label
November 24, 2014
07:59 EDTBIIBBiogen resumed with an Outperform at Leerink
Subscribe for More Information
November 19, 2014
07:52 EDTBIIBInforma Business Information to hold a conference
Subscribe for More Information
07:21 EDTBIIBBiogen price target lowered to $400 from $425 at Credit Suisse
Credit Suisse lowered Biogen's price target to $400 from $425 based on Gilenya PPMS risk but retains its Outperform rating based on the quality of earnings growth and pipeline.
November 13, 2014
10:42 EDTBIIBSummer Street chief scientific officer holds an analyst/industry conference call
Subscribe for More Information
November 12, 2014
08:13 EDTBIIBBoston Biotech to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use